Literature DB >> 22987154

Level of cdk5 expression predicts the survival of relapsed multiple myeloma patients.

Zachary Levacque, Jesusa L Rosales, Ki-Young Lee.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22987154      PMCID： PMC3507504          DOI： 10.4161/cc.21886

Source DB:  PubMed          Journal:  Cell Cycle        ISSN： 1551-4005            Impact factor:   4.534


× No keyword cloud information.
  12 in total

1.  The controlling role of ATM in homologous recombinational repair of DNA damage.

Authors:  C Morrison; E Sonoda; N Takao; A Shinohara; K Yamamoto; S Takeda
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

2.  RNAi screen of the druggable genome identifies modulators of proteasome inhibitor sensitivity in myeloma including CDK5.

Authors:  Yuan Xiao Zhu; Rodger Tiedemann; Chang-Xin Shi; Holly Yin; Jessica E Schmidt; Laura A Bruins; Jonathan J Keats; Esteban Braggio; Chris Sereduk; Spyro Mousses; A Keith Stewart
Journal:  Blood       Date:  2011-02-02       Impact factor: 22.113

3.  Cyclin-dependent kinase 5 activity controls cell motility and metastatic potential of prostate cancer cells.

Authors:  Christopher J Strock; Jong-In Park; Eric K Nakakura; G Steven Bova; John T Isaacs; Douglas W Ball; Barry D Nelkin
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

Review 4.  Extraneuronal roles of cyclin-dependent kinase 5.

Authors:  Jesusa L Rosales; Ki-Young Lee
Journal:  Bioessays       Date:  2006-10       Impact factor: 4.345

5.  Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib.

Authors:  George Mulligan; Constantine Mitsiades; Barb Bryant; Fenghuang Zhan; Wee J Chng; Steven Roels; Erik Koenig; Andrew Fergus; Yongsheng Huang; Paul Richardson; William L Trepicchio; Annemiek Broyl; Pieter Sonneveld; John D Shaughnessy; P Leif Bergsagel; David Schenkein; Dixie-Lee Esseltine; Anthony Boral; Kenneth C Anderson
Journal:  Blood       Date:  2006-12-21       Impact factor: 22.113

6.  Oncomine 3.0: genes, pathways, and networks in a collection of 18,000 cancer gene expression profiles.

Authors:  Daniel R Rhodes; Shanker Kalyana-Sundaram; Vasudeva Mahavisno; Radhika Varambally; Jianjun Yu; Benjamin B Briggs; Terrence R Barrette; Matthew J Anstet; Colleen Kincead-Beal; Prakash Kulkarni; Sooryanaryana Varambally; Debashis Ghosh; Arul M Chinnaiyan
Journal:  Neoplasia       Date:  2007-02       Impact factor: 5.715

Review 7.  The ubiquitin-proteasome system (UPS) and the mechanism of action of bortezomib.

Authors:  Boris Cvek; Zdenek Dvorak
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

8.  A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor.

Authors:  Nicholas C Turner; Christopher J Lord; Elizabeth Iorns; Rachel Brough; Sally Swift; Richard Elliott; Sydonia Rayter; Andrew N Tutt; Alan Ashworth
Journal:  EMBO J       Date:  2008-04-03       Impact factor: 11.598

9.  Single-nucleotide polymorphisms in the promoter of the CDK5 gene and lung cancer risk in a Korean population.

Authors:  Hyo Seon Choi; Youngin Lee; Kyong Hwa Park; Jae Sook Sung; Jong-Eun Lee; Eun-Soon Shin; Jeong-Seon Ryu; Yeul Hong Kim
Journal:  J Hum Genet       Date:  2009-04-03       Impact factor: 3.172

10.  Phosphorylation of ATM by Cdk5 mediates DNA damage signalling and regulates neuronal death.

Authors:  Bo Tian; Qian Yang; Zixu Mao
Journal:  Nat Cell Biol       Date:  2009-01-18       Impact factor: 28.824
View more
  24 in total

Review 1.  The Emerging Role of Cdk5 in Cancer.

Authors:  Karine Pozo; James A Bibb
Journal:  Trends Cancer       Date:  2016-10

Review 2.  Cyclins and cyclin-dependent kinases: from biology to tumorigenesis and therapeutic opportunities.

Authors:  Mitra Zabihi; Ramin Lotfi; Amir-Mohammad Yousefi; Davood Bashash
Journal:  J Cancer Res Clin Oncol       Date:  2022-07-04       Impact factor: 4.553

3.  miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells.

Authors:  Nicola Amodio; Dina Bellizzi; Marzia Leotta; Lavinia Raimondi; Lavinia Biamonte; Patrizia D'Aquila; Maria Teresa Di Martino; Teresa Calimeri; Marco Rossi; Marta Lionetti; Emanuela Leone; Giuseppe Passarino; Antonino Neri; Antonio Giordano; Pierosandro Tagliaferri; Pierfrancesco Tassone
Journal:  Cell Cycle       Date:  2013-09-25       Impact factor: 4.534

4.  Cdk5 promotes DNA replication stress checkpoint activation through RPA-32 phosphorylation, and impacts on metastasis free survival in breast cancer patients.

Authors:  Sara Chiker; Vincent Pennaneach; Damarys Loew; Florent Dingli; Denis Biard; Fabrice P Cordelières; Simon Gemble; Sophie Vacher; Ivan Bieche; Janet Hall; Marie Fernet
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

Review 5.  Targeting cyclin-dependent kinases in human cancers: from small molecules to Peptide inhibitors.

Authors:  Marion Peyressatre; Camille Prével; Morgan Pellerano; May C Morris
Journal:  Cancers (Basel)       Date:  2015-01-23       Impact factor: 6.639

6.  Insights into the clinical value of cyclin-dependent kinase 5 in glioma: a retrospective study.

Authors:  Ruan Yushan; Chen Wenjie; Huang Suning; Dang Yiwu; Zhong Tengfei; Wickramaarachchi Mihiranganee Madushi; Luo Feifei; Zhang Changwen; Wen Xin; Gopaul Roodrajeetsing; Li Zuyun; Chen Gang
Journal:  World J Surg Oncol       Date:  2015-07-25       Impact factor: 2.754

7.  Cyclin-Dependent Kinase 5 (CDK5) Controls Melanoma Cell Motility, Invasiveness, and Metastatic Spread-Identification of a Promising Novel therapeutic target.

Authors:  Savita Bisht; Jens Nolting; Ute Schütte; Jens Haarmann; Prashi Jain; Dhruv Shah; Peter Brossart; Patrick Flaherty; Georg Feldmann
Journal:  Transl Oncol       Date:  2015-08       Impact factor: 4.243

8.  CDK5 is a major regulator of the tumor suppressor DLC1.

Authors:  Brajendra K Tripathi; Xiaolan Qian; Philipp Mertins; Dunrui Wang; Alex G Papageorge; Steven A Carr; Douglas R Lowy
Journal:  J Cell Biol       Date:  2014-12-01       Impact factor: 10.539

9.  CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1- and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis.

Authors:  Shu Zhang; Zhen Lu; Weiqun Mao; Ahmed A Ahmed; Hailing Yang; Jinhua Zhou; Nicholas Jennings; Cristian Rodriguez-Aguayo; Gabriel Lopez-Berestein; Roberto Miranda; Wei Qiao; Veera Baladandayuthapani; Zongfang Li; Anil K Sood; Jinsong Liu; Xiao-Feng Le; Robert C Bast
Journal:  PLoS One       Date:  2015-07-06       Impact factor: 3.240

10.  An immunohistochemical study of cyclin-dependent kinase 5 (CDK5) expression in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC): a possible prognostic biomarker.

Authors:  Kanglai Wei; Zhihua Ye; Zuyun Li; Yiwu Dang; Xin Chen; Na Huang; Chongxi Bao; Tingqing Gan; Lihua Yang; Gang Chen
Journal:  World J Surg Oncol       Date:  2016-02-09       Impact factor: 2.754
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.